# A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated

> **NCT07526194** · PHASE1 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 72 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 3821001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07526194
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-22
- **Primary completion:** 2026-10-02
- **Final completion:** 2026-10-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526194, "A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07526194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*